Journal of Translational and Practical Medicine regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Original Article
Evaluation of the causes of chest pain and its relationship with the cardiovascular system in COVID-19 patients
Aim: Chest pain is one of the most common complaints of patients in the emergency departments during the pandemic and non-pandemic period. Because the cause of chest pain can range, from an ordinary, harmless muscle pull to serious cardiac complication ultimately leading to cardiac arrest. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through angiotensin converting enzyme 2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, and also causing acute cardiac injury and chronic damage to the cardiovascular system. COVID-19 contributes to the development of serious cardiovascular complications such as acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. In this study, it was aimed to determine the effects of COVID-19 on the cardiovascular system by evaluating the causes of chest pain in COVID-19 patients who applied to the emergency department with chest pain. Methods: This retrospective study was conducted by examining the files of COVID-19 patients who applied to a district emergency department with chest pain. Results: The files of 102 COVID-19 patients were reviewed. The most common causes of CP were musculoskeletal system (39.2%), respiratory system (23.5%), CVS diseases (20.6%), idiopathic causes (8.8%), gastrointestinal system diseases (7%, 9). Cardiac causes are non ST-segment elevation myocardial infarction (NSTMI), arrhythmia, ST-segment elevation myocardial infarction (STEMI) and unstable angina pectoris (USAP), respectively. Troponin value was higher in patients with cardiac chest pain (p=0.02), and ferritin value was higher in patients with pneumonia (p=0.01). Conclusions: Chest pain or chest tightness is common in patients with active COVID-19. Although the causes of chest pain are due to musculoskeletal pathologies, both COVID-19 and cardiac origin chest pains due to direct cardiovascular system pathologies should be kept in mind.

1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138hospitalized patients with 2019 novel coronavirus-Infectedpneumonia in Wuhan, China.JAMA. 2020;323(11):1061-1069.doi:10.1001/jama.2020.1585
2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreakassociated with a new coronavirus of probable bat origin.Nature.2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7
3. Aktoz M, Altay H, Aslanger E, et al. Türk Kardiyoloji DerneğiUzlaşı Raporu: COVID-19 Pandemisi ve KardiyovaskülerHastalıklar Konusunda Bilinmesi Gerekenler (13 Mayıs2020).Turk Kardiyol Dern Ars. 2020;48(Suppl 1):1-87.doi:10.5543/tkda.2020.36713
4. Huang C, Wang Y, Li X, et al. Clinical features of patientsinfected with 2019 novel coronavirus in Wuhan, China.Lancet.2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
5. Gersh BJ, Braunwald E, Bonow RO. Chronic coronary arterydesease. In: Braunwald E, Zipes DP, Libby P, editors. HeartDesease: A Textbook of Cardiovasculer Medicine. 6th. ed.Philadelphia: WB Saunders; 2001.p.1272-7
6. The European Society of Cardiology. ESC Guidance for theDiagnosis and Management of CV Disease during the COVID-19Pandemic. Last updated on 21 April 2020.
7. Koç İ, Doğan Y, Doğan S, Köker S, Dökme A, Kaya A. Clinicalfollow up of patients admitting to pulmonary clinic with chestpain. Selçuk Tıp Derg. 2015;31(3): 118-120
8. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristicsof Coronavirus Disease 2019 in China.N Engl J Med.2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
9. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses andthe cardiovascular system: acute and long-term implications.EurHeart J. 2020;41(19):1798-1800. doi:10.1093/eurheartj/ehaa231
10. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascularmetabolic diseases on COVID-19 in China.Clin Res Cardiol.2020;109(5):531-538. doi:10.1007/s00392-020-01626-9
11. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138Hospitalized Patients With 2019 Novel Coronavirus-InfectedPneumonia in Wuhan, China.JAMA. 2020;323(11):1061-1069.doi:10.1001/jama.2020.1585
12. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity ofcoronavirus disease 2019: a model-based analysis. Lancet InfectDis. 2020;20(6):669-677. doi:10.1016/S1473-3099(20)30243-7
13. Palmieri L, Andrianou X, Bella A, et al. Characteristics ofCOVID-19 patients dying in Italy Report based on available dataon March 20th, 2020. COVID-19 Surveillance Group. Availableat: https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf. Accessed Mar 23, 2020.
14. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the riskof patients with COVID-19: evidence from meta-analysis.Aging(Albany NY). 2020;12(7):6049-6057. doi:10.18632/aging.103000
15. Richardson S, Hirsch JS, Narasimhan M, et al. Presentingcharacteristics, comorbidities, and outcomes among 5700 patientshospitalized with COVID-19 in the New York City Area.JAMA.2020;323(20):2052-2059. doi:10.1001/jama.2020.6775
16. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate andCharacteristics of Patients Dying in Relation to COVID-19in Italy.JAMA. 2020;323(18):1775-1776. doi:10.1001/jama.2020.4683
17. Zhou F, Yu T, Du R, et al. Clinical course and risk factors formortality of adult inpatients with COVID-19 in Wuhan, China: aretrospective cohort study. Lancet. 2020;395(10229):1038.
18. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors ofmortality due to COVID-19 based on an analysis of data of 150patients from Wuhan, China.Intensive Care Med. 2020;46(5):846-848. doi:10.1007/s00134-020-05991-x
19. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascularmetabolic diseases on COVID-19 in China.Clin Res Cardiol.2020;109(5):531-538. doi:10.1007/s00392-020-01626-9
20. Kunutsor SK, Laukkanen JA. Cardiovascular complications inCOVID-19: A systematic review and meta-analysis.J Infect.2020;81(2):e139-e141. doi:10.1016/j.jinf.2020.05.068
21. Chen Q, Xu L, Dai Y, et al. Cardiovascular manifestations insevere and critical patients with COVID-19.Clin Cardiol.2020;43(7):796-802. doi:10.1002/clc.23384
22. American College of Cardiology. Troponin and BNPUse in COVID-19. Available at: https://www.acc.org/latest-in cardiology/articles/2020/03/18/15/25/troponin-and-bnp use-in covid19?utm_source=accupdate&utm_medium=email_newsletter&utm_content=20200320&utm_campaign=accupdate. Accessed Mar 23, 2020.
Volume 2, Issue 2, 2023
Page : 80-84